

NOVO NORDISK A S
Form 6-K
November 08, 2011

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

November 8, 2011

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Company Announcement

7 November 2011

Novo Nordisk A/S – Share repurchase programme

On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 2 November 2011 to 31 January 2012.

Since the announcement as of 2 November 2011, the following transactions have been made under the programme:

| | Number of | Average Transaction value, | |
|--------------------------|------------------------------|-----------------------------------|------------|
| | shares purchase price | DKK | |
| Accumulated, last | 0 | 0 | |
| announcement | | | |
| 2 November 2011 | 35,000 | 567.4200 | 19,859,700 |
| 3 November 2011 | 70,000 | 579.4500 | 40,561,500 |
| 4 November 2011 | 70,000 | 593.0500 | 41,513,500 |
| Accumulated under | 175,000 | 101,934,700 | |
| the programme | | | |

On 1 November 2011 Novo Nordisk repurchased 375,000 B shares from employees. The transaction amounted to DKK 0.2 billion and was related to the general employee share programme outside of Denmark from 2008. The shares in this transaction were not part of the Safe Harbour repurchase programme, but were part of the overall DKK 12.0 billion repurchase programme.

Other transactions related to Novo Nordisk’s incentive programmes have resulted in a sale by Novo Nordisk of 79,700 B shares in the period from 27

Company Announcement no 71 / 2011

Page 1 of 2

| | | | | |
|-------------------------|---------------|---------------|-----------------|----------|
| Novo Nordisk A/S | Novo Allé | Telephone: | Internet: | CVR no: |
| Investor Relations | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
| | Denmark | Telefax: | | |
| | | +45 4444 6626 | | |

October 2011 to 4 November 2011. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 22,194,874 treasury shares, corresponding to 3.8% of the share capital. The total amount of shares in the company is 580,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 12.0 billion during 2011 and January 2012. As of 4 November 2011, Novo Nordisk has repurchased a total of 15,656,205 B shares equal to a transaction value of DKK 9,311,993,336.

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media:

Anne Margrethe Hauge

Tel: (+45) 4442 3450

amhg@novonordisk.com

Investors:

Klaus Bülow Davidsen

Tel: (+45) 4442 3176

klda@novonordisk.com

Frank Daniel Mersebach

Tel: (+45) 4442 0604

fdni@novonordisk.com

Lars Borup Jacobsen

Tel: (+45) 3075 3479

lbpj@novonordisk.com

In North America:

Ken Inchausti

Tel: (+1) 609 514 8316

kiau@novonordisk.com

Jannick Lindegaard

Tel: (+45) 4442 4765

jlis@novonordisk.com

Company Announcement no 71 / 2011

Page 2 of 2

| | | | | |
|-------------------------|---------------|---------------|-----------------|----------|
| Novo Nordisk A/S | Novo Allé | Telephone: | Internet: | CVR no: |
| Investor Relations | 2880 Bagsværd | +45 4444 8888 | novonordisk.com | 24256790 |
| | Denmark | Telefax: | | |
| | | +45 4444 6626 | | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: November 8, 2011

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer
